论文部分内容阅读
目的观察双歧三联活菌胶囊在感染幽门螺杆菌消化道疾病患者中的治疗效果。方法选取2012年1月~2014年6月在我院进行诊断和治疗的幽门螺杆菌阳性的慢性胃炎和消化性溃疡患者80例，随机分为观察组与对照组，每组各40例，对照组给予雷贝拉唑三联疗法10d，观察组在给予雷贝拉唑三联疗法7d后，改为给予双歧三联活菌胶囊7d。停药1个月后比较两组患者幽门螺杆菌清除率及临床疗效。结果观察组H.pylori根除率90%显著高于对照组70%(<0.05)。临床疗效评价：观察组总有效率达95豫，对照组总有效率77.5豫，差异显著(P<0.05)。结论在感染幽门螺杆菌消化道疾病患者中应用双歧三联活菌胶囊可提高H.pylori根除率，更有效缓解临床症状。“,”Objective To observe the treatment ef ect of Bifid Triple Viable capsules used in patients with digestive tract disease who infected Helicobacte rpyloric. Methods 80 Helicobacter pylori positive chronic gastritis and peptic ulcer patients who were diagnosed and treated in our hospital from 2012 January to 2014 June were randomly divided into observation group and control group with 40 cases in each group.The control group was given Rabeprazole triple therapy for 10 days, while the observation group was given Rabeprazole triple therapy for 7 days,?then changed to a given Bifid Triple Viable capsule for 7 days. One month after Withdrawal Helicobacter pylori eradication rate and clinical ef icacy were compared between the two groups.Results The H.pylori eradication?rate in the observation group was 90%, significantly higher than 70%in the control group ( <0.05).The total ef ective rate was 95%in the observation group, and 77.5%in the control group.The dif erence was statistical y significant( <0.05). Conclusion Bifid Triple Viable capsules can improve the eradication rate of H.pylori application,more ef ectively relieve the clinical symptoms of patients with digestive tract disease.